Here, we show that dual treatment combining HER2-targeted therapy with the CDK7 inhibitor THZ1 strongly inhibits HER2+ BC cell growth and increases apoptosis in cancer cells that exhibit resistance to HER2-targeted therapies. Here, ERBB2 is linked to breast cancer.